Novartis ESMO Event Presentation
Proportion of patients (%)
Objective response rate (ORR) was higher and duration of response
(DOR) was longer with Pluvicto versus ARPI change¹
177 Lu-PSMA-617 (n = 71)
ARPI change (n = 74)
21.1
2.7
45.9
32.4
31.0
29.6
12.2
15.5
Complete
response
Partial response
Stable disease
Progressive
disease
Best ORR in soft tissue per RECIST v1.1
ORR in soft tissue:
50.7% vs. 14.9%2
Median DOR in soft
tissue³, months:
6.8
2.8
13.6 vs. 10.14
Unknown
1. Among patients with measurable disease at baseline. 2. 95% CI: 50.7% (38.6, 62.8) vs. 14.9% (7.7, 25.0) 3. In patients with complete response or partial response 4. 95% CI: 13.6 (11.6, NE), n = 36 vs. 10.0 (4.6, NE), n = 11
19 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION
NOVARTIS | Reimagining MedicineView entire presentation